SUPPLEMENTAL FIGURE 1. Flowchart of I-PET available for qualitative central review.



Abbreviations: FUP= follow-up; ICF= informed consent form; I-PET= interim ^{18}F-FDG PET; PD= progressive disease

SUPPLEMENTAL FIGURE 2. Flowchart of EoT-PET available for qualitative central review.



Abbreviations: EoT-PET= end-of-treatment ^{18}F-FDG PET; FUP= follow-up; ICF= informed consent form; PD= progressive disease

SUPPLEMENTAL TABLE 1

Interobserver agreement of ordinal DS in I-PET					
	DS 1	**DS 2**	**DS 3**	**DS 4**	**DS 5**
DS 1	88	40	25	7	3
DS 2	46	43	26	7	1
DS 3	19	20	21	8	0
DS 4	10	9	11	38	10
DS 5	1	0	0	8	24

Percentage exact agreement = ((88 + 43 + 21 + 38 + 24)/465)*100% = (214/465)*100% = 46.0%

Percentage agreement (+1, -1) = ((88 + 43 + 21 + 38 + 24 + 46 + 40 + 20 + 26 + 8 + 10)/465)*100% = (364/465)*100% = 78.3%

SUPPLEMENTAL TABLE 2

Interobserver agreement of ordinal DS in EoT-PET					
	DS 1	**DS 2**	**DS 3**	**DS 4**	**DS 5**
DS 1	128	49	22	3	4
DS 2	57	37	16	1	0
DS 3	16	17	16	7	0
DS 4	5	7	11	16	8
DS 5	0	0	0	14	23

Percentage exact agreement = ((128 + 37 + 16 + 16 + 23)/457)*100% = (220/457)*100% = 48.1%

Percentage agreement (+1, -1) = ((128 + 37 + 16 + 16 + 23 + 57 + 49 + 17 + 16 + 14 + 8)/457)*100% = (381/457)*100% = 83.4%

SUPPLEMENTAL TABLE 3

Interobserver agreement of specific nodal and extranodal localizations in EoT-PET.

	Number baseline positive	Number of discrepancies at EoT-PET	Agreement on negativity (absolute)	Agreement on positivity (absolute)	Percentage overall agreement‡	Related to baseline prevalence§
Nodal						
Para-aortic†	397	17	884	13	98.1	4.3%
Cervical†	286	6	903	5	99.3	2.1%
Iliac†	267	8	899	7	99.1	3.0%
Axillary†	220	1	909	4	99.9	0.5%
Supraclavicular†	213	2	908	4	99.8	0.9%
Inguinal†	204	5	908	1	99.5	2.5%
Mediastinal*	202	5	442	8	98.9	2.5%
Mesenteric	188	17	429	11	96.3	9.0%
Hilar*†	142	8	897	1	99.1	5.6%
Spleen*	114	6	442	8	98.7	5.4%
Other	105	6	450	1	98.7	5.7%
Waldeyer	48	1	456	0	99.8	2.1%
Extranodal						
Other extranodal*	123	13	431	10	97.1	10.6%
Skeletal*	90	8	441	5	98.2	8.9%
GI*	62	6	444	6	98.7	9.7%
Lung*	54	3	445	6	99.3	5.6%
Liver*	38	2	453	1	99.6	5.3%
Pleura*	25	0	456	0	100.0	0.0%
Skin	13	1	456	0	99.8	7.7%
CNS	0	0	456	1	100.0	0.0%

Abbreviations: CNS= central nervous system; EoT-PET= end-of-treatment positron emission tomography; GI= gastrointestinal

* Totals not 457 or 914, because of missing values or localization scored as unclear.

† Right and left are summed and presented together.

‡Percentage overall agreement: (number of agreement on positivity + number of agreement on negativity) / (number of discrepancies + number of agreement on positivity + number of agreement on negativity)*100%.

§Related to baseline prevalence: (number of discrepancies/number baseline positive)*100%.

SUPPLEMENTAL TABLE 4

Overview of PET/CT scanner types used in the HOVON84 study.

Manufacturer	PET/CT Model	I-PET (*n* = 465)	EoT-PET (*n* =457)
GE Medical Systems	Discovery RX	*n* = 3	*n* = 1
	Discovery ST	*n* = 8	*n* = 8
	Discovery STE	*n* = 24	*n* = 26
	Discovery 690	*n* = 1	*n* = 3
Philips	Allegro Body (C)	*n* = 5	NA
	Gemini TF TOF 16	*n* = 37	*n* = 48
	Gemini TF TOF 64	*n* = 62	*n* = 71
	Gemini TF (C)	*n* = 16	*n* = 10
	Gemini GXL 10	*n* = 5	*n* = 3
	Gemini GXL 16	*n* = 23	*n* = 22
	Guardian Body	*n* = 1	NA
Siemens	Biograph 6	*n* = 17	*n* = 16
	Biograph 16	*n* = 6	*n* = 6
	Biograph 40	*n* = 112	*n* = 100
	Biograph 64	*n* = 72	*n* = 79
	Biograph 128	*n* = 2	*n* = 2
CTI PET Systems	Biograph mCT	*n* = 71	*n* = 62

Abbreviations: EoT-PET= end-of-treatment positron emission tomography; I-PET= interim positron emission tomography; NA: not applicable

SUPPLEMENTAL TABLE 5

GRRAS checklist for reporting reliability and agreement studies.

Table 1
Guidelines for Reporting Reliability and Agreement Studies (GRRAS).

		Reported on page number(s):
TITLE AND ABSTRACT	1. Identify in title or abstract that interrater/intrarater reliability or agreement was investigated.	1,3
INTRODUCTION	2. Name and describe the diagnostic or measurement device of interest explicitly.	5,6
	3. Specify the subject population of interest.	5
	4. Specify the rater population of interest (if applicable).	methods 6
	5. Describe what is already known about reliability and agreement and provide a rationale for the study (if applicable).	5
METHODS	6. Explain how the sample size was chosen. State the determined number of raters, subjects/objects, and replicate observations.	6
	7. Describe the sampling method.	5,6
	8. Describe the measurement/rating process (e.g. time interval between repeated measurements, availability of clinical information, blinding).	6
	9. State whether measurements/ratings were conducted independently.	6
	10. Describe the statistical analysis.	7
RESULTS	11. State the actual number of raters and subjects/objects which were included and the number of replicate observations which were conducted.	7-9
	12. Describe the sample characteristics of raters and subjects (e.g. training, experience).	7,8 + methods
	13. Report estimates of reliability and agreement including measures of statistical uncertainty.	8,9
DISCUSSION	14. Discuss the practical relevance of results.	10-14, esp 13,14
AUXILIARY MATERIAL	15. Provide detailed results if possible (e.g. online)	Supplementals

"Reprinted from *J Clin Epidemiol*, 64 (1), Kottner J, Audigé L, Brorson S, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed, Table 1, Page 98, Copyright 2011 with permission from Elsevier."